Aat

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Anatomy, Acute-phase proteins, Branches of biology, Alpha-1 antitrypsin, Medical specialties, Aat, Serpin, Alpha 1, Liver disease, Alpha-1 antitrypsin deficiency, Alpha-1 Antitrypsin Deficiency and Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATLD), Belcesiran, RNAi and Dicerna’s GalXC™ RNAi Platform, Dicerna Pharmaceuticals, Inc., ALPHA-1 ANTITRYPSIN DEFICIENCY AND ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE (AATLD), BELCESIRAN, RNAI AND DICERNA’S GALXC™ RNAI PLATFORM, DICERNA PHARMACEUTICALS, INC.

Data from this interim analysis showed dose-dependent reductions in serum alpha-1 antitrypsin (AAT) with administration of a single dose of belcesiran.

Key Points: 
  • Data from this interim analysis showed dose-dependent reductions in serum alpha-1 antitrypsin (AAT) with administration of a single dose of belcesiran.
  • The primary treatment evaluation period for the final dose cohort (12.0 mg/kg) of belcesiran in the Phase 1 trial is ongoing.
  • Alpha-1 antitrypsin (AAT) deficiency is a rare genetic condition caused by mutations in the SERPINA1 gene that results in disease of the liver and lungs.
  • Belcesiran is a clinical-stage, subcutaneously administered, investigational GalXC RNAi therapy targeting alpha-1 antitrypsin (AAT) that is in development for the treatment of AAT deficiency-associated liver disease (AATLD).

Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

Retrieved on: 
Monday, April 6, 2020
Health, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Acute phase proteins, Medical specialties, Biology, Alpha-1 antitrypsin, Gene expression, RNA, Alnylam Pharmaceuticals, Liver disease, Hyperoxaluria, Alpha 1, Aat, ALN-AAT02 and DCR-A1AT, Alpha-1 Antitrypsin Deficiency-Associated Liver Disease, Lumasiran, Nedosiran, Primary Hyperoxaluria (PH), RNAi, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Inc.

Specifically, the new agreements allow for Alnylam and Dicerna to join forces in areas of common interest, namely alpha-1 liver disease and primary hyperoxaluria, said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.

Key Points: 
  • Specifically, the new agreements allow for Alnylam and Dicerna to join forces in areas of common interest, namely alpha-1 liver disease and primary hyperoxaluria, said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.
  • Under the development and commercialization agreement, Alnylams ALN-AAT02 and Dicernas DCR-A1AT, investigational RNAi therapeutics, each in Phase 1/2 development, will be explored for the treatment of alpha-1 liver disease.
  • Dicerna will select which product candidate(s) to advance in development for the treatment of patients with alpha-1 liver disease.
  • ALN-AAT02 and DCR-A1AT are investigational, subcutaneously administered RNAi therapeutics targeting alpha-1 antitrypsin (A1AT) in development for the treatment of A1AT deficiency-associated liver disease (alpha-1 liver disease).

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

Retrieved on: 
Friday, January 24, 2020
Medical specialties, Acute phase proteins, Alpha-1 antitrypsin, Anatomy, Organ systems, CSL Behring, Alpha 1, Aat, Behring, Trypsin

CSL Behring is now able to provide the therapy to patients in Denmark with immediate effect.

Key Points: 
  • CSL Behring is now able to provide the therapy to patients in Denmark with immediate effect.
  • Respreeza is a highly purified alpha-1 protein, derived from human plasma and indicated to treat patients with Alpha 1 Antitrypsin Deficiency (AATD).
  • AATD is a hereditary condition marked by a lack of the Alpha 1 Antitrypsin protein, whose main function is to protect the lungs from inflammation.
  • The Danish Medicines Council estimates that this decision could benefit up to 80 patients in Denmark who, currently, are eligible for treatment with AAT therapy.

American Academy of Thermology (AAT) Announces Several Medical Education Funding Opportunities

Retrieved on: 
Tuesday, August 6, 2019
Aat

GREENVILLE, S.C., Aug. 6, 2019 /PRNewswire-PRWeb/ --The AAT has several programs available for the funding of Medical Thermology Education .

Key Points: 
  • GREENVILLE, S.C., Aug. 6, 2019 /PRNewswire-PRWeb/ --The AAT has several programs available for the funding of Medical Thermology Education .
  • Medical Thermology indications range from complex, chronic pain, dysautonomia, domestic violence, breast risk assessment, oral-systemic disorders, and veterinary applications.
  • The AAT Medical Thermology Education Funding Programs are directed toward medical institutions, physicians, and universities in accordance with the AAT's Mission of promulgating Medical Thermology education.
  • The American Academy of Thermology has committed to provide access to its medical training and education programs to organized medicine, including aligned institutions, that need assistance in medical thermology training, if the scope of their activities is within the Mission of the AAT and their activities will further the AAT's Mission to promulgate Medical Thermology education.

American Academy of Thermology (AAT) Releases Full Agenda for 2019 Annual Meeting & Scientific Session Sep. 7-8 in Atlanta, GA

Retrieved on: 
Wednesday, May 15, 2019
Breast imaging, Infrared imaging, Medical imaging, Non-contact thermography, Pseudoscience, Meeting, Aat, Greenville, South Carolina

GREENVILLE, S.C., May 15, 2019 /PRNewswire-PRWeb/ --The American Academy of Thermology (AAT), which is the premiere organization in North America for the scientific development, healthcare training and clinical application of medical infrared imaging, has announced the full agenda for the organization's 2019 Annual Meeting & Scientific Session.

Key Points: 
  • GREENVILLE, S.C., May 15, 2019 /PRNewswire-PRWeb/ --The American Academy of Thermology (AAT), which is the premiere organization in North America for the scientific development, healthcare training and clinical application of medical infrared imaging, has announced the full agenda for the organization's 2019 Annual Meeting & Scientific Session.
  • Attendees are also invited to a special "Meet and Mingle" reception on the evening of September 7.
  • In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Thermology.
  • More information on the AAT's 2019 Annual Meeting & Scientific Session, along with accommodation discounts for AAT members and non-members, is available at http://annualmeeting.aathermology.org .

American Academy of Thermology (AAT) to Hold 2019 Annual Meeting & Scientific Session Sep. 7-8 in Atlanta, GA

Retrieved on: 
Tuesday, February 19, 2019
Greenville, South Carolina, Greenville, South Carolina metropolitan area, Bon Secour, Aat, Atlanta, Geography of the United States, Cities in the United States

This is the first year that the AAT will be holding its Annual Meeting & Scientific Session in Atlanta.

Key Points: 
  • This is the first year that the AAT will be holding its Annual Meeting & Scientific Session in Atlanta.
  • Previously, it was held at the Bon Secours St. Francis Hospital campus at the Bernadine Center in Greenville, SC.
  • "We are excited about holding our holding our 2019 Annual Meeting & Scientific Session at Atlanta's Emory University Conference Center, which is an outstanding facility," commented Jeffrey J. Lefko, Executive Director of the AAT.
  • More information on the AAT's 2019 Annual Meeting & Scientific Session, along with accommodation discounts for AAT members and non-members, will be published in the coming weeks at http://annualmeeting.aathermology.org .